Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients.

摘要: Background. Multitargeted tyrosine kinase inhibitors (TKIs) represent a new class of target-specific antineoplastic agents. These agents show some specific adverse events such as fatigue/asthenia, anorexia/loss appetite, dysgeusia, diarrhea/abdominal pain, hypothyroidism, hypertension, myelosuppression, and stomatitis. Materials Methods. A systematic search was performed on PubMed online database using combination MESH terms free text words, “sunitinib” OR “sorafenib” “axitinib” “cabozantinib” “pazopanib” “regorafenib” “nintedanib” “vatalanib” combined through the use Boolean operator AND with key words “stomatitis” “mucositis,” (i) human subjects, (ii) written in English language, (iii) reporting about incidence stomatitis or oral mucositis. Results. The any grade 35.2% for sunitinib, 20.52% sorafenib, 20.63% axitinib, 34.21% cabozantinib. All showed high rates low-grade (G1-G2), while onset severe (G3-G4) very low. Conclusions. Analysis reports patients treated cabozantinib clear prevalence 1 2. data differ from those conventional chemotherapy which mucositis is predominantly 3 4.